Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00607425
NCT00607425TerminatedNot Applicable

Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening

Scottsdale Healthcare0 sites40 target enrollmentStarted: August 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
40
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a pilot study to test the feasibility of using gene expression from saliva to identify patients with early-stage non-small cell lung cancer (NSCLC).

The primary objective of this study is to compare gene expression profiles from saliva from healthy controls and patients with early-stage non-small cell lung cancer.

To be eligible, patients with non-small cell lung cancer, must not yet have received treatment for their cancer (surgical removal, chemotherapy, or radiation therapy). Health control participants may participate if they meet eligibility criteria listed below.

Eligible enrollees will be asked to submit a one time saliva sample and complete a study questionaire.

Study Design

Study Type
Observational
Observational Model
Case Control

Eligibility Criteria

Ages
40 Years to 79 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients with untreated stage I-II NSCLC OR Healthy control subjects: with a > 20 pack year history of cigarette smoking OR Never smokers (defined as less than 100 cigarettes over subject's lifetime)
  • •The investigators recognize that pathologic confirmation is not always available prior to surgical resection of a lung mass. To account for this, subjects with a suspicious lung mass concerning for lung cancer, can be enrolled on this trial, and submit a saliva sample prior to surgical resection (ideally within 45 days of planned surgery).
  • •Adults age 40-79
  • •Ability to understand the investigational nature of the study and sign the informed consent in accordance with institutional and FDA guidelines

Exclusion Criteria

  • •No active pulmonary infection, i.e. bronchitis or pneumonia for 6 months
  • •No use of steroid inhalers for > 6 months
  • •No other prior malignancy is allowed except for adequately treated basal or squamous cell skin cancer, in situ cervical cancer, or other cancers from which the patient has been disease-free for 5 years

Investigators

Sponsor Class
Other

Similar Trials

Not yet recruiting
Not Applicable
To check for neonatal infections using saliva
CTRI/2017/04/008427Spot Healthcare Solutions Pvt Ltd100
Unknown
Not Applicable
Salivary Transcriptome Biomarkers for Early Diabetes DetectionPre-diabetesType II DiabetesInsulin Resistance
NCT02673762PeriRx180
Withdrawn
Not Applicable
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell TransplantMucositisOral MucositisMultiple MyelomaAmyloidosis
NCT02589860Sherif S. Farag
Unknown
Not Applicable
Salivary Profiling in Infants Treated for Suspected Sepsis: The SPITSS StudyNewborn Infection
NCT05490212Tufts Medical Center5,000
Active, not recruiting
Not Applicable
Group A Streptococcus Saliva Study
NCT06473506The Hospital for Sick Children200